Cargando…

Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial

The US Food and Drug Association has approved interferon-α (IFN-α) and interleukin-2 (IL-2) as adjuvant therapy in malignant melanoma. The objective of the study was to compare efficacy and safety of subcutaneous interferon-α with continuous intravenous IL-2 in Chinese patients with malignant melano...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shenglong, Wu, Xixi, Chen, Peng, Pei, Yi, Zheng, Ke, Wang, Wei, Qiu, Enduo, Zhang, Xiaojing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Clinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430598/ https://www.ncbi.nlm.nih.gov/pubmed/30664008 http://dx.doi.org/10.1097/CAD.0000000000000741

Ejemplares similares

Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial
por: Li, Shenglong, et al.
Publicado: (2019)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis
por: Liu, Fei, et al.
Publicado: (2020)

Phantom Limb Pain and Sensations in Chinese Malignant Tumor Amputees: A Retrospective Epidemiological Study
por: Jiang, Shuang, et al.
Publicado: (2021)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis
por: Li, Shenglong, et al.
Publicado: (2021)

Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma
por: Li, Wei, et al.
Publicado: (2017)

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
por: Curti, Brendan, et al.
Publicado: (2020)

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004)

Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial
por: Dixon, S, et al.
Publicado: (2006)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Ilex hainanensis Merr targets ITGAV to suppress the proliferation and metastasis of osteosarcoma cells
por: Pei, Yi, et al.
Publicado: (2019)

The α Chemokine, Interleukin 8, Inhibits the Antiviral Action of Interferon α
por: Khabar, Khalid S.A., et al.
Publicado: (1997)

[Retracted] Ursolic acid suppresses the biological function of osteosarcoma cells
por: Pei, Yi, et al.
Publicado: (2023)

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome
por: Atzpodien, J, et al.
Publicado: (2003)

Intraoral malignant melanoma
por: Mittal, Neelam, et al.
Publicado: (2017)

Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
por: Atzpodien, J, et al.
Publicado: (2002)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
por: Hauschild, A, et al.
Publicado: (2001)

Effective modulation of CD4(+)CD25(+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2
por: Liu, Guangxian, et al.
Publicado: (2012)

Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p
por: Li, Shenglong, et al.
Publicado: (2019)

Primary malignant melanoma of the esophagus
por: Karapiperis, Dimitrios, et al.
Publicado: (2022)

Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma
por: Yoshida, N, et al.
Publicado: (2002)

The cytokines interleukin-6 and interferon-α induce distinct microglia phenotypes
por: West, Phillip K., et al.
Publicado: (2022)

Long noncoding RNA TTN-AS1 enhances the malignant characteristics of osteosarcoma by acting as a competing endogenous RNA on microRNA-376a thereby upregulating dickkopf-1
por: Li, Shenglong, et al.
Publicado: (2019)

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
por: Radny, P, et al.
Publicado: (2003)

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
por: Kähler, Katharina C., et al.
Publicado: (2018)

Verrucous-Keratotic Malignant Melanoma (VKMM)
por: Damianov, Nikolay, et al.
Publicado: (2017)

Giant gastric metastasis of malignant melanoma
por: Yoshimoto, Takaaki, et al.
Publicado: (2021)

Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
por: Ashraf, Farhan, et al.
Publicado: (2016)

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study
por: Espinosa, Enrique, et al.
Publicado: (2016)

Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon α-2b
por: Lan, Shijie, et al.
Publicado: (2021)

Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells
por: Cho, Chi Hyun, et al.
Publicado: (2015)

Interleukin-6 and Interferon-α Signaling via JAK1–STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States
por: Danziger, Oded, et al.
Publicado: (2018)

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998)

Transcriptomic analyses reveal the underlying pro-malignant functions of PTHR1 for osteosarcoma via activation of Wnt and angiogenesis pathways
por: Li, Shenglong, et al.
Publicado: (2017)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocyte) and tamoxifen
Publicado: (2000)

Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis
por: Kaczyński, Tomasz, et al.
Publicado: (2019)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_or006cslfd1h37qopml40rnung